Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PMM2 | O15305 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532105 | 1.00 | TDP1 (0.43) | TDP1ALDH1A1PMM2MPITSHR | |
| SCHEMBL9452627 | 0.84 | ALDH1A1 (0.52) | TDP1ALDH1A1PMM2MPITSHR | |
| SCHEMBL240574 | 0.84 | TDP1 (0.52) | TDP1ALDH1A1TSHRGPR35LMNA | |
| SCHEMBL1161245 | 0.79 | TDP1 (0.43) | TDP1ALDH1A1TSHRGPR35LMNA | |
| SCHEMBL30267557 | 0.79 | TDP1 (0.43) | TDP1ALDH1A1TSHRGPR35LMNA | |
| SCHEMBL29557370 | 0.77 | GPR35 (0.59) | TDP1ALDH1A1TSHRGPR35MAPT | |
| SCHEMBL2843518 | 0.77 | TDP1 (0.45) | TDP1ALDH1A1TSHRGPR35LMNA | |
| SCHEMBL1249766 | 0.77 | TSHR (0.59) | TDP1ALDH1A1PMM2MPITSHR | |
| SCHEMBL1056952 | 0.77 | TDP1 (0.45) | TDP1ALDH1A1PMM2MPITSHR | |
| SCHEMBL98247 | 0.77 | GPR35 (0.59) | TDP1ALDH1A1TSHRGPR35MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117645603-A | P300 bromodomain inhibitor, pharmaceutical composition and application thereof | 复旦大学 | 2024-03-05 | — | — | CN | claimed |
| CN-110305058-A | A kind of 4- bromine carbazole preparation method | 安徽秀朗新材料科技有限公司 | 2019-10-08 | — | — | CN | claimed |
| CN-108126656-A | For the modified activated carbon absorbent of benzene in Adsorption wastewater from chemical industry | 北京益清源环保科技有限公司 | 2018-06-08 | — | — | CN | claimed |
| US-20260150574-A1 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-12528833-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-12509628-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368667-A1 | USP1 INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-20250354060-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250351719-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| EP-0270964-B1 | PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES | BAYER AG (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-4868347-A | SOLVENT EXTRACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| EP-0270964-A2 | Process for obtaining substituted fluorobenzenes | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509628-B2 | Organic electroluminescent materials and devices | LBR, OXSR1, GLRA1 | TDP1 4586/4885ALDH1A1 2062/4885PMM2 4749/4885 |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | RECQL, AR, DHX35 | TDP1 2109/4885ALDH1A1 319/4885PMM2 3878/4885 |
| US-20250351719-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, PDCD2L | TDP1 2976/4885ALDH1A1 855/4885PMM2 1666/4885 |
| US-20250368667-A1 | USP1 INHIBITOR | USP1, USP2, USP28 | TDP1 1694/4885ALDH1A1 644/4885PMM2 3197/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TDP1 3096/4885ALDH1A1 4162/4885PMM2 419/4885 |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | TDP1 2580/4885ALDH1A1 1515/4885PMM2 4486/4885 |
| US-20260150574-A1 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | OXER1, OR10J3, OPRD1 | TDP1 4700/4885ALDH1A1 450/4885PMM2 4759/4885 |
| US-12528833-B2 | Organic electroluminescent materials and devices | LBR, CHRM1, OPRD1 | TDP1 3987/4885ALDH1A1 2117/4885PMM2 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.